{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:14:48Z","timestamp":1788480888084,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jcp.0b013e3181eeb600","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T12:13:40Z","timestamp":1283429620000},"page":"487-495","source":"Crossref","is-referenced-by-count":48,"title":["Paliperidone Extended-Release in Schizoaffective Disorder"],"prefix":"10.1097","volume":"30","author":[{"given":"Carla M.","family":"Canuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schooler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Carothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Kosik-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1176\/ajp.151.6.144","article-title":"The acute schizoaffective psychoses. 1933.","volume":"151","author":"Kasanin","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2007.07.009","article-title":"Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders.","volume":"106","author":"Cheniaux","year":"2008","journal-title":"J Affect Disord"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jad.2007.09.009","article-title":"Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach.","volume":"108","author":"Peralta","year":"2008","journal-title":"J Affect Disord"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1192\/bjp.177.5.421","article-title":"Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms.","volume":"177","author":"Harrow","year":"2000","journal-title":"Br J Psychiatry"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0924-9338(01)00559-4","article-title":"Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences.","volume":"16","author":"Benabarre","year":"2001","journal-title":"Eur Psychiatry"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1399-5618.2007.00564.x","article-title":"Schizoaffective disorder: diagnostic issues and future recommendations.","volume":"10","author":"Malhi","year":"2008","journal-title":"Bipolar Disord"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1521\/suli.2006.36.1.35","article-title":"The cycle of schizoaffective disorder, cognitive ability, alcoholism, and suicidality.","volume":"36","author":"Goldstein","year":"2006","journal-title":"Suicide Life Threat Behav"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0006-3223(03)00178-1","article-title":"Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.","volume":"54","author":"Potkin","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1176\/ajp.156.10.1590","article-title":"Suicidal behavior in patients with schizophrenia and other psychotic disorders.","volume":"156","author":"Radomsky","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone Study Group. Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies.","volume":"21","author":"Keck","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/ps.2009.60.2.210","article-title":"Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients.","volume":"60","author":"Olfson","year":"2009","journal-title":"Psychiatr Serv"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","article-title":"Pharmacologic treatment of hospitalized patients with schizoaffective disorder.","volume":"53","author":"Flynn","year":"2002","journal-title":"Psychiatr Serv"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1055\/s-0029-1202265","article-title":"The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.","volume":"42","author":"Berwaerts","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"S3","key":"R18-2-20210128","first-page":"S648","article-title":"Absorption, metabolism and excretion of a single oral dose of 1 mg paliperidone in a population of five healthy male subjects.","volume":"15","author":"Vermeir","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.","volume":"27","author":"Kramer","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of two dose ranges of paliperidone ER in the treatment of subjects with schizoaffective disorder.","volume":"71","author":"Canuso","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness.","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br J Soc Clin Psychol"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-9964(02)00335-3","article-title":"The InterSePT scale for suicidal thinking reliability and validity.","volume":"63","author":"Lindenmayer","year":"2003","journal-title":"Schizophr Res"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications.","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4088\/JCP.08m04227","article-title":"McLean-Harvard international first-episode project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients.","volume":"70","author":"Salvatore","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0920-9964(89)90036-4","article-title":"Distinction of schizoaffective from schizophrenic profile: independent validation.","volume":"2","author":"Lindenmayer","year":"1989","journal-title":"Schizophr Res"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psychres.2005.08.012","article-title":"Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.","volume":"143","author":"Lake","year":"2006","journal-title":"Psychiatry Res"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1176\/ps.46.12.1254","article-title":"Heavy utilization of inpatient and outpatient services in a public mental health service.","volume":"46","author":"Kent","year":"1995","journal-title":"Psychiatr Serv"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201010000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:16:08Z","timestamp":1618035368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201010000-00002"}},"subtitle":["A Randomized, Controlled Study Comparing a Flexible Dose With Placebo in Patients Treated With and Without Antidepressants and\/or Mood Stabilizers"],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181eeb600","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}